Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 2/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 2/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | CHRNA4 | P43681 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 0.90 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.90 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.90 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.90 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.90 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.90 |
| ▸ | MEN1 | O00255 | 2/20 | 0.90 |
| ▸ | LMNA | P02545 | 1/20 | 0.90 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trimebutine SCHEMBL14273976 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1PDE4DNR1I2CHRM2 | |
| Trimebutine SCHEMBL7428847 | 0.99 | OPRM1 (0.98) | OPRM1OPRD1PDE4DNR1I2CHRM2 | |
| Trimebutine SCHEMBL28274910 | 0.95 | ALDH1A1 (1.00) | OPRM1OPRD1PDE4DNR1I2CHRM2 | |
| Trimebutine SCHEMBL67225 | 0.95 | ALDH1A1 (1.00) | OPRM1OPRD1PDE4DNR1I2CHRM2 | |
| Trimebutine SCHEMBL5011979 | 0.95 | ALDH1A1 (1.00) | OPRM1OPRD1PDE4DNR1I2CHRM2 | |
| Trimebutine SCHEMBL1652810 | 0.95 | ALDH1A1 (1.00) | OPRM1OPRD1PDE4DNR1I2CHRM2 | |
| SCHEMBL16522145 | 0.93 | OPRM1 (0.88) | OPRM1OPRD1PDE4DNR1I2CHRM2 | |
| SCHEMBL14317655 | 0.91 | OPRM1 (0.83) | OPRM1OPRD1PDE4DNR1I2CHRM2 | |
| Trimebutine SCHEMBL738779 | 0.90 | OPRM1 (0.81) | OPRM1OPRD1PDE4DNR1I2CHRM2 | |
| SCHEMBL23977102 | 0.90 | OPRM1 (0.81) | OPRM1OPRD1PDE4DNR1I2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3528 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| EP-4731194-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT | CSP Technologies, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| EP-4687805-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING ACTIVATED CARBON OR A DERIVATIVE THEREOF | CSP Technologies, Inc. (US) | 2026-02-11 | — | — | EP | claimed |
| US-20260027008-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING ACTIVATED CARBON OR A DERIVATIVE THEREOF | CSP TECHNOLOGIES, INC. | 2026-01-29 | — | — | US | claimed |
| EP-4680203-A1 | COMPOSITIONS FOR SUSTAINED RELEASE OF POORLY SOLUBLE ACTIVE INGREDIENTS | Prolevi Bio AB (SE) | 2026-01-21 | — | — | EP | claimed |
| WO-2025264260-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT | CSP TECHNOLOGIES, INC. (US) | 2025-12-26 | — | — | WO | claimed |
| US-12458602-B2 | Realizing the nano-amorphous state of materials inside nano-porous templates | THE CHINESE UNIVERSITY OF HONG KONG (CN) | 2025-11-04 | — | — | US | claimed |
| EP-4154879-B1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NICOTINE WITHDRAWAL SYMPTOMS | KOREA INST SCI & TECH (KR) | 2025-09-10 | — | — | EP | claimed |
| CN-120078838-A | Traditional Chinese medicine composition with function of improving spleen and stomach and preparation method thereof | 广州市康培健母婴用品有限公司 | 2025-06-03 | — | — | CN | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| US-5700410-A | Method of manufacturing wax matrices | NIPPON SHINYAKU CO., LTD. (JP) | 1997-12-23 | — | — | US | claimed |
| US-5693337-A | OIL IN WATER EMULSION CONTAINING DRUG, LECITHIN, CITRIC ACID, AND METHIONINE, PHENYLALANINE, SERINE, AND/OR HISTIDINE; SYNERGISTIC, STORAGE STABILITY | WAKAMOTO PHARMACEUTICAL CO., LTD. (JP) | 1997-12-02 | — | — | US | claimed |
| EP-0806949-A1 | NEW PHARMACEUTICAL COMPOSITION CONTAINING TRIMEBUTINE AND PREPARATION PROCESS | JOUVEINAL LABORATOIRES (FR) | 1997-11-19 | — | — | EP | claimed |
| EP-0580860-B1 | METHOD OF MANUFACTURING SOLID DISPERSION | NIPPON SHINYAKU CO LTD (JP) | 1997-10-22 | — | — | EP | claimed |
| WO-1996023493-A1 | NEW PHARMACEUTICAL COMPOSITION CONTAINING TRIMEBUTINE AND PREPARATION PROCESS | JOUVEINAL LABORATORIES (FR) | 1996-08-08 | — | — | WO | claimed |
| EP-0707492-A1 | H 2? ANTAGONIST-GASTROINTESTINAL MOTILITY AGENT COMBINATIONS | MERCK & CO. INC. (US) | 1996-04-24 | — | — | EP | claimed |
| EP-0700678-A1 | Stable lipid emulsion | Wakamoto Pharmaceutical Co., Ltd. (JP) | 1996-03-13 | — | — | EP | claimed |
| WO-1995001803-A1 | H2 ANTAGONIST-GASTROINTESTINAL MOTILITY AGENT COMBINATIONS | MERCK & CO., INC. (US) | 1995-01-19 | — | — | WO | claimed |
| EP-0109554-B1 | PROCESS FOR OBTAINING LIGHT AND CRISPY SOYBEAN PROTEINS OF AGREEABLE TASTE | Ferrero, Aldo (IT) | 1986-10-15 | — | — | EP | claimed |
| EP-0100983-A1 | Steroid compounds with choleretic activity, a process for their preparation, and therapeutic compounds which contain them as active principle | PROTER S.p.A. (IT) | 1984-02-22 | — | — | EP | claimed |